Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.
| Added by | llasorsa |
|---|---|
| Group name | EquipeMY |
| Item Type | Attachment |
| Title | Texte intégral |
| URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.00686 |
| Accessed | 2022/08/30 - 17:14:59 |
| Date Added | 2022/08/30 - 15:14:59 |
| Date Modified | 2022/08/30 - 15:14:59 |
| Parent item | Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study |
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de